PTGS1 and cancer: Their anti-inflammatory activity is primarily mediated through the inhibition of cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2), an enzyme that converts arachidonic acid (ARA) into prostaglandins (PGs), thereby promoting the development of inflammation [9], cancer [10], and a variety of CVDs [11].